S&P 500 falls on pressure from retail stocks, weak jobless claims
SAN DIEGO—Tandem Diabetes Care Inc. (NASDAQ:TNDM) Executive Vice President and Chief Operating Officer, Jean-Claude Kyrillos, has recently increased his stake in the company. According to a filing with the Securities and Exchange Commission, Kyrillos acquired 10,538 shares of Tandem Diabetes common stock on March 7, 2025. The shares were purchased at a weighted average price of $18.1217, totaling approximately $190,966. The purchase comes as the stock trades near its 52-week low of $17.64, having declined about 58% over the past six months. According to InvestingPro analysis, the stock currently appears undervalued based on its Fair Value metrics.
The transaction was executed in multiple trades, with prices ranging between $18.115 and $18.13 per share, as noted in the filing. This purchase brings Kyrillos’s total holdings to 10,538 shares, reflecting a direct ownership stake in the company. The insider purchase aligns with broader management actions, as InvestingPro data shows management has been actively buying back shares.
Investors often closely monitor insider transactions like these, as they can provide insight into the executive’s confidence in the company’s future performance. For deeper insights into TNDM’s valuation and 12+ additional ProTips, including detailed insider trading analysis, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Tandem Diabetes Care has been the focus of multiple analyst downgrades following its latest earnings report and revenue guidance. The company reported a fourth-quarter 2024 revenue of $252.4 million, marking a 20.6% increase and surpassing the consensus estimate of $249.7 million. However, concerns arose due to its 2025 revenue guidance, projecting a 10-11% increase to between $997 million and $1.007 billion, which some analysts found underwhelming. Morgan Stanley (NYSE:MS), Citi, and Bernstein all downgraded their ratings on the stock, citing various challenges and uncertainties.
Morgan Stanley downgraded the stock to Equalweight, reducing the price target to $22, expressing concerns about modest growth and competition. Citi also downgraded the stock from Buy to Neutral, setting a new price target of $24, while noting the company’s market share increase in the U.S. to 22.2% year-over-year. Bernstein shifted its rating from Outperform to Market Perform, lowering the price target to $25, highlighting market share loss and competitive pressures.
The downgrades reflect apprehensions about Tandem Diabetes Care’s strategic shifts, including its transition from distributors to direct sales overseas, and the potential complications these could introduce. Despite a rise in international sales, the company’s U.S. sales fell short of expectations, adding to the cautious outlook from analysts. Tandem’s gross margins and adjusted EBITDA also raised concerns, with the latter significantly below consensus estimates, contributing to the tempered analyst sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.